<DOC>
	<DOCNO>NCT00005647</DOCNO>
	<brief_summary>RATIONALE : SU5416 may stop growth head neck cancer stop blood flow tumor . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining SU5416 chemotherapy may kill cancer cell . PURPOSE : Phase I trial study effectiveness SU5416 paclitaxel treat patient recurrent , locally advanced , metastatic cancer head neck .</brief_summary>
	<brief_title>SU5416 Paclitaxel Treating Patients With Recurrent , Locally Advanced Metastatic Cancer Head Neck</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose safety SU5416 paclitaxel patient recurrent metastatic head neck cancer . - Determine antiangiogenesis effect combination regimen patient . - Determine toxicity , pharmacodynamic effect , pharmacokinetic parameter combination . OUTLINE : This dose escalation study . Patients receive paclitaxel IV one hour day 1 SU5416 IV one hour day 1 4 . Treatment continue weekly absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos paclitaxel SU5416 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 6 patient experience dose limit toxicity . PROJECTED ACCRUAL : A total 34 patient accrue study within 9-15 month .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Semaxinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Metastatic locoregionally recurrent malignancy head neck ( include salivary gland thyroid ) incurable surgery radiotherapy At least two distinct tumor mass OR One tumor mass least 3 cm diameter No brain metastases No pulmonary metastasis site disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : WBC least 3,500/mm3 Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin great 9.0 g/dL Hepatic : PT PTT normal OR INR ratio le 1.1 Bilirubin less 1.5 mg/dL AST ALT less 2 time upper limit normal Renal : Creatinine le 1.5 mg/dL Creatinine clearance great 60 mL/min Cardiovascular : No New York Heart Association class III IV heart disease No uncompensated coronary artery disease No history myocardial infarction severe unstable angina within past 6 month No severe peripheral vascular disease No deep venous thrombosis arterial thrombosis within past 6 month No know hypercoagulable syndrome predisposition venous arterial clot Pulmonary : No pulmonary embolism within past 6 month Other : No prior cerebral hemorrhage Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 3 week since palliative chemotherapy ( 6 week mitomycin nitrosoureas ) recover At least 4 week since combine chemoradiotherapy recover Must recover prior taxanes Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior large field radiotherapy recover Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>thyroid gland medullary carcinoma</keyword>
	<keyword>anaplastic thyroid cancer</keyword>
	<keyword>recurrent thyroid cancer</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>stage III follicular thyroid cancer</keyword>
	<keyword>metastatic squamous neck cancer occult primary squamous cell carcinoma</keyword>
	<keyword>recurrent hypopharyngeal cancer</keyword>
	<keyword>stage III adenoid cystic carcinoma oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent verrucous carcinoma oral cavity</keyword>
	<keyword>recurrent mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>recurrent adenoid cystic carcinoma oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent lymphoepithelioma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent lymphoepithelioma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent verrucous carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
</DOC>